This article is a review of Breast Cancer in Women Under 40
Younger women with breast cancer present important management challenges due in part to differences in both tumor biology and individual patient factors. In his article, Peppercorn provides a comprehensive overview of these issues with a particular focus on questions surrounding systemic therapy options.
Adjuvant Endocrine Therapy Choices
Younger age at diagnosis is typically associated with an increased likelihood of estrogen receptor (ER)-negative breast cancer compared to the cancers in older women, yet the majority of women under 40 are diagnosed with ER-positive cancer. Therefore, decision-making about adjuvant endocrine therapy in premenopausal women with breast cancer is important. Selection of endocrine therapy is complicated, however, by uncertainties associated with a lack of data regarding optimal antiestrogen treatment for premenopausal women, as well as difficulties in assessment of ovarian function in amenorrheic women.
The Early Breast Cancer Trialists’ Collaborative Group has shown that adjuvant tamoxifen(Drug information on tamoxifen) is equally effective in both premenopausal and postmenopausal women and results in statistically significant improvements in disease recurrence and breast cancer mortality compared to no adjuvant endocrine therapy. Because aromatase inhibitor (AI) therapy is ineffective in women whose ovaries are functional and produce estrogen, tamoxifen is considered the standard of care for premenopausal women with ER-positive breast cancer in the United States. As outlined in the review article, there are a number of outstanding questions about choice of adjuvant endocrine therapy in young women that are currently being addressed by ongoing clinical trials.
Although the standard of care for premenopausal women is tamoxifen, some patients are being offered treatment with ovarian suppression in conjunction with AI therapy, either because they have a contraindication or intolerance to tamoxifen or because their physician believes that the AIs are superior based on data in postmenopausal women.
One concern with this approach is treatment with luteinizing hormone–releasing hormone agonists may result in incomplete ovarian suppression, either initially or over time. Therefore, women treated with ovarian suppression should have their ovarian function monitored serially. Serum estradiol(Drug information on estradiol) assessment is challenging in this patient population because standard immunoassays for estradiol are inaccurate at low serum concentrations. In addition, immunoassays can result in falsely elevated estradiol levels in women treated with the steroidal AI exemestane(Drug information on exemestane) (Aromasin) because of metabolite interactions in the assay. More accurate mass spectroscopy–based estradiol assays are available commercially, but these assays are more expensive, have a longer turnaround time, and can be less sensitive at very low estradiol levels.[7,8]
Choosing an adjuvant endocrine therapy for premenopausal women who develop chemotherapy-induced amenorrhea is also challenging. Although these women may be thought to be menopausal, and therefore candidates for AI therapy, ovarian estrogen production may persist even in the setting of prolonged amenorrhea. That is, chemotherapy-induced ovarian failure following chemotherapy is not necessarily permanent as patients may later regain ovarian function and even fertility.
In a retrospective study of 45 breast cancer patients with chemotherapy-induced amenorrhea age 40 and older, about one-quarter of women with chemotherapy-induced amenorrhea developed recurrent ovarian function when treated with an AI. The authors of that study recommended that women under the age of 40 not be treated with an AI alone, regardless of apparent ovarian failure following chemotherapy, and that older women who are postmenopausal based on biochemical assessment be monitored serially for at least the first 6 months of AI therapy. As mentioned above, however, there remain substantial technical limitations with currently available commercial estradiol assays, which make monitoring more challenging.
Assessment of CYP2D6 Metabolizer Status
For those women treated with tamoxifen, the question of whether or not to assess CYP2D6 metabolizer status is timely and controversial. Tamoxifen, a relatively weak selective estrogen receptor modulator, is a prodrug that is metabolized in the liver to a number of active metabolites, including 4-hydroxytamoxifen and endoxifen (4-hydroxy-N-desmethyltamoxifen). Although these two equipotent metabolites are more active antiestrogens than tamoxifen, endoxifen is present at higher concentrations in most women taking tamoxifen.
CYP2D6 is a noninducible, highly polymorphic P450 enzyme that converts tamoxifen to endoxifen. Of the 80 different major alleles of CYP2D6 that have been identified to date, many cause decreased or absent CYP2D6 activity. Patients can be divided into poor, intermediate, extensive, and ultrarapid metabolizer cohorts based on their CYP2D6 genotype. Approximately 7% of Caucasians are homozygous for an inactive, variant allele designated *4; in a prospective observational study of breast cancer patients treated with tamoxifen, those who were homozygous for this poor-metabolizer genotype (*4/*4) had lower levels of endoxifen than those with wild-type (extensive metabolizer) (*1/*1) genotypes.
CYP2D6 Genotype: What Are the Clinical Implications?
Multiple retrospective studies have been conducted evaluating the effect of CYP2D6 genotype on breast cancer outcomes. In the first, tamoxifen-treated ER-positive breast cancer patients homozygous for the poor-metabolizer genotype were more likely to experience breast cancer recurrence than those patients homozygous for wild-type enzyme.[14,15] The authors hypothesized that patients who were poor metabolizers did not activate tamoxifen to endoxifen and therefore received less or no benefit from tamoxifen. Results from some subsequent studies have confirmed this finding.[16,17] Two studies, however, demonstrated that CYP2D6 *4/*4 patients had better outcomes when treated with tamoxifen compared to those with wild-type CYP2D6 genotype, which is the opposite of the initial findings.[18,19]
These investigations suggest an important role for CYP2D6 activity in tamoxifen metabolism, although further studies are required. Until these contradictory results have been resolved, however, it remains unclear how the results of CYP2D6 testing should be applied clinically—especially in the premenopausal population for whom there are limited available alternative therapies.
As mentioned by Peppercorn, multiple antidepressants, including paroxetine, fluoxetine, duloxetine(Drug information on duloxetine) (Cymbalta), bupropion, and possibly sertraline(Drug information on sertraline) are known to be moderate or potent inhibitors of CYP2D6. Studies have demonstrated lower levels of endoxifen in women treated concomitantly with several of these antidepressants and tamoxifen.[13,20] Since alternative treatments for depression or hot flashes that do not affect CYP2D6 activity are indeed available—including venlafaxine (Effexor), citalopram(Drug information on citalopram), and gabapentin—known CYP2D6 inhibitors can generally be avoided in tamoxifen-treated patients.
Overall, this excellent overview of management issues for breast cancer patients under 40 years of age highlights the major questions surrounding choices of adjuvant systemic therapy. Treatment choices are dependent on breast cancer biology (receptor status) as well as patient factors (ovarian function and desire for future fertility). As many unanswered questions remain, it is important to continue to enroll subjects in clinical trials focused on this important patient population.
Financial Disclosure: Dr. Henry has received research funding from AstraZeneca.